Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Key Highlights
- ➤Mean PLA2R antibody reduction reached 70% at Week 12 with 200 mg budoprutug
- ➤Five of 13 patients achieved immunologic remission at Week 12
- ➤600 mg produced 98% Week 4 peripheral CD20+ B-cell suppression
- ➤High-proteinuria patients cleared budoprutug at least twofold faster, supporting higher doses
- ➤MCD case patient achieved three-year steroid-free remission after 100 mg budoprutug
Expert Statements
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“Current treatment strategies fail to induce complete remission in most patients with pMN, underscoring the need for more effective treatments”
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“While complete remission often takes more than a year to achieve, changes in PLA2R antibody levels can be appreciated much earlier in the treatment course and serve as an early indicator of therapeutic efficacy.”
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“Reductions in PLA2R antibody levels have been shown to correlate with downstream improvements in proteinuria, and ultimately complete remission.”
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“In the PrisMN study, the low-dose budoprutug cohort demonstrated encouraging PLA2R antibody reductions and immunologic remission rates in patients with moderate to severe pMN.”
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“These early results are highly promising, and I look forward to seeing how these data evolve as follow-up continues and higher-dose cohorts read out.”
Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
“These data provide further evidence that targeting CD19 with budoprutug may be a compelling approach in the treatment of pMN.”
Aoife Brennan, President and Chief Executive Officer of Climb Bio
“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses”
Aoife Brennan, President and Chief Executive Officer of Climb Bio
“The observed pharmacokinetics confirm that patients with pMN have increased clearance of budoprutug compared to patients who do not have proteinuria.”
Aoife Brennan, President and Chief Executive Officer of Climb Bio
“We are encouraged by the greater exposure and deeper B-cell depletion we are seeing at these early time points in the 600 mg cohort.”
Aoife Brennan, President and Chief Executive Officer of Climb Bio
“As enrollment and follow-up continue, we look forward to sharing additional data.”
Aoife Brennan, President and Chief Executive Officer of Climb Bio
“Beyond pMN, we are encouraged by the sustained steroid-free remission reported in the MCD case, supporting further investigation of budoprutug in additional glomerular diseases and highlighting its potential impact across different B-cell mediated diseases.”
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027
Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation
Get started
Create a free account to read the full story.